{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Marker Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"MRKR"},"Address":{"label":"Address","value":"3200 SOUTHWEST FREEWAY,SUITE2500, HOUSTON, Texas, 77027, United States"},"Phone":{"label":"Phone","value":"+1 713 400-6400"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart."},"CompanyUrl":{"label":"Company Url","value":"http//www.markertherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Gerald Garrett","title":"Vice President-Clinical Operations"},{"name":"Juan F. Vera","title":"President, CEO, CFO, Chief Accounting Officer"},{"name":"Maria-Bernadette Madel","title":"Director-Operations & External Communications"},{"name":"Monic Stuart","title":"Chief Medical Officer"},{"name":"Patricia Allison","title":"Head-Clinical Operations"},{"name":"Tsvetelina Pencheva Hoang","title":"Vice President-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}